PET/CT for staging lung cancer: costly or cost-saving?

PETCT in lung cancer staging

Activated protein C: cost-effective or costly?

The authors offer a commentary on the study by Dhainaut et al. on the cost-effectiveness of activated protein C in severe sepsis. Using data from "real world" conditions, the results of this economic evaluation are consistent with previous analyses, and highlight the need for "real world" investigations of new health technologies in critical care.

Coronary stenting: costly or cost-effective?

In today's health care climate, decisions about new technologies need to reflect measures of cost as well as clinical benefit. By estimating the cost-effectiveness ratio for a new treatment compared to a current standard (e.g., stenting as compared to conventional PTCA), it is possible to decide whether the new treatment represents an efficient use of limited health care resources. In this anal...

Lung cancer staging

During this interactive hands-on workshop the participants will view complete imaging examinations (CT of chest, abdomen, brain, MRI of brain, chest, adrenals, musculoskeletal system, PET-CT, bone scintigraphy etc.) on workstations in a clinical routine setting and discuss findings with two tutors. Cases will include those with typical findings as well as pitfalls and problems. Particular atten...

Staging of lung cancer.

arl in the history of thoracic surgery, attempts were made to classify patients as to the extent of disease, in order to avoid unnecessary surgery. Evarts A. Graham,1 the surgeon who first successfully removed a carcinomatous lung in 1933, listed in 1944 the following signs of inoperabiity: (1) the presence of a bloody pleural effusion; (2) paralysis of the ipsilateral hemidiaphragm; (3) paraly...